Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Medicina (Kaunas) ; 60(7)2024 Jun 21.
Artigo em Inglês | MEDLINE | ID: mdl-39064448

RESUMO

Background and Objectives: The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection may cause acute respiratory failure, but also remains responsible for many other pathologies, including electrolyte disorders. SARS-CoV-2 infection causes disorders in many systems and can disrupt water homeostasis with thirst and appetite abnormalities. Dysnatremia affects prognosis, and may be associated with mortality in patients admitted to an intensive care unit (ICU) diagnosed with SARS-CoV-2. Materials and Methods: The study included 209 patients admitted to the ICU between 12 April 2021 and 1 March 2022 who were over 18 years old and diagnosed with SARS-CoV-2 infection by clinical and thoracic tomography findings or with a positive reverse transcription polymerase chain reaction (RT-PCR) test result. The laboratory markers, treatment modalities, nutritional, and respiratory support also for outcome evaluation, length of stay in the ICU, total hospitalization duration, and mortality in the ICU were recorded. The laboratory marker comparison was made using admission with the final assessment performed before the time of mortality in the ICU or after discharge. Results: Inotropic requirements among patients were high, which reflected mortality in the ICU. Hypernatremia presence was associated with an increase in enteral support, the inotropic support requirement, and mortality. Hypernatremia was correlated with diabetes mellitus, chronic renal failure, and a longer duration under mechanical ventilation. Conclusions: Hypernatremia was an important risk factor in ICU patients hospitalized for SARS-CoV-2 infection, which was also affected by the treatment regimens given themselves. This complex relationship underlies the importance of proper electrolyte management, especially in patients who were under severe stress and organ failure.


Assuntos
COVID-19 , Hipernatremia , Unidades de Terapia Intensiva , Humanos , COVID-19/mortalidade , COVID-19/complicações , COVID-19/terapia , Masculino , Feminino , Pessoa de Meia-Idade , Estudos Retrospectivos , Hipernatremia/mortalidade , Hipernatremia/sangue , Idoso , Unidades de Terapia Intensiva/estatística & dados numéricos , SARS-CoV-2 , Adulto , Cuidados Críticos/métodos , Biomarcadores/sangue , Mortalidade Hospitalar , Tempo de Internação/estatística & dados numéricos , Prognóstico
2.
Medicina (Kaunas) ; 60(4)2024 Apr 22.
Artigo em Inglês | MEDLINE | ID: mdl-38674325

RESUMO

Background and Objectives: Thoracic epidural catheterization (TEC) can be both uncomfortable and fearful for patients when performed awake with the thought that the procedure may be painful. The aim of this study was to assess the effect of low-dose intravenous ketamine administration on pain and anxiety during the TEC procedure. Materials and Methods: Sixty patients were randomly divided into two groups to receive intravenous (IV) placebo (Group P) and IV low-dose (0.15 mg/kg) ketamine (LDK) (Group K) 3 min before the procedure in a double-blind manner. A visual analog scale (VAS) was used to measure anxiety (VAS-A) and pain (VAS-P) scores. Vital parameters were monitored before premedication (T1), 20 min after premedication (T2), during skin anesthesia (T3), during TEC (T4), and 5 min after TEC (T5). VAS-A values were recorded at T1, T3, T4, and T5 periods, and VAS-P levels were noted at T3, T4, and T5 periods. Results: During TEC (T4), both VAS-P and VAS-A were significantly lower in Group K (p < 0.001). The mean VAS-A value was 10.6 mm lower, and the mean VAS-P value was 9 mm lower in Group K than in Group P at the T4 time point. Additionally, the mean VAS-P value was 7.7 mm lower in Group K compared to Group P at the T3 time point (p < 0.001). Both groups showed a statistically significant difference in VAS-A measurements when compared at their respective time points (p < 0.001). However, only Group P demonstrated a statistically significant difference in VAS-P measurements (p < 0.001). VAS-P values remained stable in Group K. The number of patients who did not recall the procedure was significantly higher in Group K (p < 0.001). Furthermore, the number of patients who would consent to the same procedure in the future was significantly higher in Group K (p = 0.007). Conclusions: A preprocedural LDK (0.15 mg/kg) can effectively prevent anxiety and pain experienced by patients during the TEC procedure. Administration of LDK may provide a more comfortable procedure process without causing ketamine-induced side effects (hemodynamic, respiratory, and psychological).


Assuntos
Ansiedade , Ketamina , Medição da Dor , Humanos , Ketamina/administração & dosagem , Ketamina/uso terapêutico , Masculino , Feminino , Método Duplo-Cego , Ansiedade/prevenção & controle , Ansiedade/tratamento farmacológico , Adulto , Pessoa de Meia-Idade , Medição da Dor/métodos , Analgésicos/uso terapêutico , Analgésicos/administração & dosagem , Cateterismo/métodos , Cateterismo/efeitos adversos , Dor/tratamento farmacológico , Dor/prevenção & controle , Dor/psicologia , Anestesia Epidural/métodos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA